BCM
LOXO

BlueCrest Capital Management’s Loxo Oncology, Inc LOXO Stock Holding History

BlueCrest Capital Management’s Portfolio LOXO Stock Details LOXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-4,015
Closed -$463K – 2041
2018
Q1 		$463K Buy
+4,015
New +$427K 0.01% 824

Other funds holding LOXO

AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

BlueCrest Capital Management's LOXO Position: Q2 2018 in Review

BlueCrest Capital Management sold out of Loxo Oncology, Inc (LOXO) in Q2 2018, closing a stake of 4,015 shares — an estimated $463K sold.

BlueCrest Capital Management first reported a position in LOXO in Q1 2018 and held it in 1 quarter. The position peaked at $463K in Q1 2018. 213 funds tracked by Wall St. Rank hold LOXO as of Q2 2018.

  • BlueCrest Capital Management reported no remaining Loxo Oncology, Inc position as of Q2 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 4,015 Loxo Oncology, Inc shares in Q2 2018, an estimated $463K.
  • BlueCrest Capital Management first reported a position in Loxo Oncology, Inc in Q1 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Loxo Oncology, Inc position peaked at $463K in Q1 2018.
  • 213 funds tracked by Wall St. Rank held Loxo Oncology, Inc as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.